Stem cells for heart disease? First things first

The linkurl:Keystone Symposium;http://www.the-scientist.com/blog/display/23134/ I?m at this week in Santa Fe is billed as being about two related subjects: the molecular mechanisms of cardiac disease and the molecular mechanisms of regeneration. And while the talks on regeneration ? that translates here roughly into stem cell therapy ? are mostly scheduled for today (Wednesday) and tomorrow, the use of stem cells to regenerate the heart is already the loud buzz at poster sessions, and is at least a whisper in talks whose subjects suggest they about pure molecular mechanisms. Take, for example, linkurl:Randall Moon,;http://www.hhmi.org/research/investigators/moon_bio.html who opened the meeting with a discussion of the role of the Wnt/beta catenin signaling pathway in zebrafish tail fin regeneration. Before you knew it, Moon had jumped very quickly to the suggestion that such a pathway might be a target for improving cardiac regeneration strategies using progenitor cells. He backed that idea with he called ?science fair experiments? showing that in a mouse model, intraperitoneal injection of Wnt-5alpha triples the number of human cells in the bone marrow. So when linkurl:Christine Seidman,;http://www.hhmi.org/research/investigators/seidmance.html who studies the genetic triggers of heart failure, made a plea at the beginning of her talk last night, it resonated with me: Before we rush into regeneration strategies for the heart, ?maybe it would be better to figure out how to fix the hearts we?ve got,? she said. I?m not sure how many of the eager stem cell researchers ? or the self-identified ?overeager cardiac surgeon? who asked a question this morning ? understood the distinction she was trying to make. I heard it as a warning that if we don?t understand molecular mechanisms of cardiac disease well enough, adding stem cells, whether they?re adult or embryonic, will only muddle the picture and be unhelpful. Kenneth Chien, who was lured from UCSD to Harvard last year to direct the Massachusetts General Hospital?s Cardiovascular Research Center, does study stem cells, but his message also threw a bit of cold water on the enthusiasm. He?s working to take the Islet-1 cardiovascular progenitor story, which was the subject of his talk, into the human setting. His results so far with this cell line, including finding them in atrial tissue following neonatal pediatric surgery of congenital heart defects and then renewing them successfully in vitro (see Laugwitz et al Nature 2005 Feb 10;433(7026):647-53), have generated quite a lot of attention. His definitions and approach seemed to ruffle some feathers in the audience, but he seemed to hold his own. The fact that Chien, someone with solid stem cell credentials, started his own talk with a warning that these are dangerous times for stem cell researchers -- alluding to what he called 'Koreagate' -- brought me back to Seidman?s comments. ?I want to inject a note of caution,? he said. ?The ongoing clinical studies essentially support not the differentiation of stem cells into beating cardiomyocytes, but a paracrine effect.? It may not be the stem cells themselves, but some factors they secrete, or an environment they create, or some such. In other words, if we figure out those molecular mechanisms as Seidman suggested, we might find methods that aren?t necessarily stem cell-based to regenerate the heart.

Stem cells for heart disease? First things first

The Scientist ARCHIVES

Become a Member of

Keywords

Meet the Author

Ivan Oransky

Related Research Resources

Bunsen Burners and Bad Hair Days

Research Resources

Podcasts

Webinars

Videos

Infographics

eBooks

Characterizing Immune Memory to COVID-19 Vaccination

Meet Honeybun and Breeze Through Viscometry in Formulation Development

Taking the Guesswork Out of Quality Control Standards

PFAS: The Forever Chemicals

Products

Product News

Metrion Biosciences launches NaV1.9 high-throughput screening assay to strengthen screening portfolio and advance research on new medicines for pain

Biotium Unveils New Assay Kit with Exceptional RNase Detection Sensitivity

Atelerix signs exclusive agreement with MineBio to establish distribution channel for non-cryogenic cell preservation solutions in China

Thermo Scientific™ Centrifuges with GreenCool Technology